DaVita (NYSE:DVA) Releases FY 2025 Earnings Guidance

Key Points

• DaVita has issued its FY 2025 earnings guidance, projecting an EPS of 10.200-11.300, compared to a consensus estimate of 10.733.
• The stock's current consensus rating is a "Hold" with a price target of $167.40, following recent changes from analysts including a downgrade by Truist and an upgrade by Wall Street Zen.
• DaVita's shares are currently trading at $140.98, with a market capitalization of $10.64 billion and a P/E ratio of 13.97.

DaVita (NYSE:DVA - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 10.200-11.300 for the period, compared to the consensus earnings per share estimate of 10.733. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Truist Financial set a $148.00 price objective on shares of DaVita in a research report on Friday. Barclays lowered their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday. Finally, Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th.

DaVita Stock Performance

Shares of DaVita stock traded up $1.86 during midday trading on Friday, hitting $129.55. The company had a trading volume of 949,567 shares, compared to its average volume of 883,366. The business's 50 day simple moving average is $140.02 and its two-hundred day simple moving average is $146.79. The stock has a market cap of $9.26 billion, a PE ratio of 12.74, a P/E/G ratio of 0.88 and a beta of 1.09. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.20. DaVita has a 1-year low of $126.07 and a 1-year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the previous year, the company earned $2.00 earnings per share. The business's revenue was up 6.1% compared to the same quarter last year. As a group, equities analysts predict that DaVita will post 10.76 EPS for the current fiscal year.

Insider Activity

In other DaVita news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.00% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DaVita stock. NewEdge Advisors LLC lifted its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 20.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 511 shares of the company's stock after buying an additional 88 shares during the quarter. NewEdge Advisors LLC's holdings in DaVita were worth $78,000 at the end of the most recent quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.